期刊
ONCOLOGIST
卷 22, 期 4, 页码 480-483出版社
WILEY
DOI: 10.1634/theoncologist.2016-0354
关键词
CEP110-FGFR1 fusion protein; Eosinophilia; Acute myeloid leukemia; Imatinib; Dasatinib
类别
This brief communication reports on a patient with an exceedingly rare 8p11 (eight-p-eleven) myeloproliferative syndrome (EMS) with CEP110-FGFR1 rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by increasing blood counts and reducing the need for transfusions. This report demonstrates that the second-generation TKI may provide a therapeutic option for elderly and frail EMS patients who cannot be offered aggressive therapy, including allogeneic hematopoietic cell transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据